Japan approves Dupixent for kids 6–11 with severe asthma, improving lung function and reducing flare-ups.

Japan has approved Dupixent (dupilumab) for children aged 6 to 11 with uncontrolled moderate-to-severe bronchial asthma linked to type 2 inflammation, making it the first biologic to show improved lung function in this age group in a Phase 3 trial. The approval, based on the VOYAGE trial, shows a 54% to 65% reduction in severe asthma exacerbations and improved lung function by 4.68% to 5.32% versus placebo when added to standard therapy. The drug targets IL-4 and IL-13, key drivers of type 2 inflammation, and is intended for children not adequately controlled by existing treatments.